Cognition Disorders, Multiple Sclerosis
Conditions
Brief summary
Multiple sclerosis (MS) is the most common progressive neurologic disorder to occur in adults of working-age. Despite longstanding recognition of cognitive impairment as a symptom of MS, two obstacles in measurement have limited understanding its biological basis, and therefore identifying targeted options for management. First is the absence of a sensitive and precise measure of cognitive impairment. Second is the absence of an index of disease status linked to brain pathophysiology and cognitive performance. This project overcomes both obstacles to link cognitive impairment to MS disease biomarkers. The absence of a sensitive and precise measure of cognitive impairment, along with the absence of an index of disease status linked to brain pathophysiology and cognitive performance, limits the understanding of the biological basis for multiple sclerosis (MS). This project overcomes both obstacles to link cognitive function to MS disease biomarkers, and provides preliminary evaluation of a disease modifying therapy (Tecfidera) for preserving cognitive function.
Interventions
DIAGNOSTIC_TESTSiemens Biograph mMR (molecular MR)
5mCi of the radiotracer FDG administered intravenously as a bolus over 30s. After injection, emission data will be collected for 60 min,
DIAGNOSTIC_TESTfMRI
High-resolution T1-weighted structural image will be acquired using an MP2RAGE sequence. Subject will beasked to look at the cross hair on a screen andnot fixate on any one thought.
DIAGNOSTIC_TESTDiffusion Spectrum Imaging (DSI)
DSI allows for more accurate characterization of diffusion,overcomes traditional dMRI artifacts, and is capable of more precise and detailedcharacterization of white matter fibers
Sponsors
NYU Langone Health
Study design
Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations. 2. Male and Female subjects between 18 and 45 years 3. WRAT-4 Reading \[127\] standard score \> 85 4. Able to undergo neuroimaging data collection procedures. For MS Participants 5. Definite diagnosis of RRMS \[128\] 6. EDSS of 0 to 6.0 7. Adequate vision as as reported by the participant (with correction if applicable) 8. Clinically prescribed Tecfidera, Tysabri or Ocrevus therapy by treating neurologist, with first dose being within 3 months + 14 days from baseline visit 9. At baseline visit, concurrent medications to be kept constant over three months prior to data collection visits 10. No relapse or steroids in previous month
Exclusion criteria
1. Unable or unwilling to provide informed consent. 2. Beck Depression Inventory-Fast Screen (BDI-FS) \[129, 130\] score of 4 or more 3. Current alcohol or other substance use disorder 4. Primary psychiatric disorder that would adversely influence ability to participate 5. Other neurological condition associated with cognitive impairment (e.g., epilepsy, brain injury) 6. Other serious uncontrolled medical condition (e.g., cancer or acute myocardial infarction) 7. Learned English language after 12 years of age 8. For low absolute low lymphocyte count (ALC), USPI guidance will be utilized. For MS participants: 9. Lemtrada, Cladribine, Mitoxantrone
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| intraindividual variation (ie IIV) in reaction times across the trials of the Attention Network Test (ANT) | Baseline | Attention Network Test (ANT) is a cognitive reaction time test administered on the computer, where the subject indicates when they see a target on a screen. |
Countries
United States
Outcome results
None listed